Capmatinib Medication Guide: Daily Dosage and Administration

Capmatinib (Capmatinib), an innovative drug, is administered orally to patients in the form of film-coated tablets of a specific shape. This medication contains 150 mg (light orange-brown) or 200 mg (yellow) of capmatinib, which corresponds to 183.00 mg or 244.00 mg of capmatinib dihydrochloride monohydrate, respectively. Capmatinib has shown significant efficacy in treating certain types of cancer, such as non-small cell lung cancer.

However, determining the dose of capmatinib is not a simple matter. It takes into account the patient's weight, the severity of the condition, whether other medications are being used, and the patient's overall health. These factors will affect the metabolism and effects of drugs in the body. Therefore, doctors will take these factors into consideration to tailor the most appropriate medication plan for the patient.

Importantly, capmatinib is a prescription drug and its use must strictly follow your doctor's recommendations and the instructions on the drug label. Patients must not change the dosage or method of taking the medicine on their own to avoid unnecessary adverse reactions or affecting the therapeutic effect.

According to the clinical use guidelines of capmatinib, the recommended dosage is 400 mg twice daily. This is equivalent to taking two 200 mg capmatinib tablets each time. Capmatinib, as a selective type ib ATP competitive tyrosine kinase inhibitor, can precisely act on the MET target. In experiments, capmatinib showed strong inhibitory effects on lung cancer cell lines, with an average IC50 value as low as 0.13nM.

In addition, the pharmacokinetics of capmatinib also indicate that exposure increases approximately in a dose-proportional manner over the dose range of 200-400 mg. The drug is rapidly absorbed by the body, and peak plasma concentration (Cmax) is reached approximately 1-2 hours after taking a 400mg dose. Absorption is similar whether taken with or without food. The effective elimination half-life of capmatinib is 6.5 hours, and its plasma protein binding rate is as high as 96%.